恒瑞医药获BMS152亿美元合作
2026-07-24 04:52:33
据界面新闻报道，百时美施贵宝（BMS）与恒瑞医药达成战略合作，涉及13个临床前项目，首付款6亿美元，潜在总交易额152亿美元。报道还称，这笔交易发生在全球专利悬崖周期下，BMS正在通过外部引进补充管线。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
国泰航空8月1日起调整燃油附加费Next article：
摩根大通上调英特尔目标价至85美元
